Hereditary Angioedema (HAE) — CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Citation(s)
Open-Label, Single-Dose Study to Evaluate the Response and Pharmacokinetics/Pharmacodynamics of Different Doses of CINRYZE® [C1 Inhibitor (Human)] For Treatment of Acute Angioedema Attacks in Children Less Than 12 Years of Age With Hereditary Angioedema